Navigation Links
Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
Date:4/16/2008

Results Support Moving Forward with a planned IND Filing for Novavax's

Seasonal Influenza Vaccine Candidate

ROCKVILLE, Md., April 16 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) said today that it has received positive results from an immunogenicity study in ferrets inoculated with the company's trivalent seasonal influenza vaccine candidate. These findings will enable Novavax to complete its planned investigational new drug ("IND") application to support initiation of a Phase II clinical trial targeted to begin in the third quarter of this year.

In the study, ferrets were inoculated with the company's trivalent seasonal influenza vaccine containing a mixture of three virus-like particles (VLPs) representing the H3N1, H1N1, and B virus strains. The vaccine induced protective antibody levels against each of the three strains represented in the vaccine in 100% of ferrets receiving a dose of 15 mcg/strain which is the standard dose for currently licensed split and subunit influenza vaccines. The vaccine candidate also induced protective antibody titers against a drifted strain in approximately 50% of ferrets inoculated. A separate toxicology study conducted in rabbits showed the trivalent vaccine was well tolerated with no unexpected side effects. The ferret and toxicology studies were conducted in collaboration with Dr. Ted Ross at the University of Pittsburgh Center for Vaccine Research and Bridge Laboratories, Gaithersburg, Maryland, respectively.

"Novavax' influenza programs are moving forward rapidly as planned," said Dr. Penny Heaton, Novavax' Chief Medical Officer and VP of Development. "In addition to the positive results from our seasonal influenza vaccine candidate announced today
'/>"/>

SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
2. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
3. Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
4. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
5. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
6. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
7. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
8. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
9. NOLabs AB Reports Success in Fight Against Bacteria Causing Urinary Tract Infection
10. Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
11. MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 Research ... the "Physician Office Laboratory Markets, 3rd Edition" ... This report, Physician Office Laboratory Markets is Kalorama,s ... IVD industry. Physician office laboratories are diverse in ... perform reimbursable, in-office pregnancy and glucose tests. Some ...
(Date:9/23/2014)... DUBLIN , September 23, 2014 /PRNewswire/ ... ) has announced the addition of the  ...  report to their offering.  ... injectable drug delivery market holds significant potential ... with vials and painful needles to the ...
(Date:9/23/2014)... -- SiteOne Therapeutics Inc. today announced the completion of its ... Management and Biobrit LLC, with additional investors Mission Bay ... financing positions SiteOne to advance its oral Na V ... its technology platform for long-acting local analgesics, pain diagnostics ... the financing, Lowell Sears (Sears Capital Management) ...
Breaking Medicine Technology:Physician Office Laboratory Markets, 3rd Edition 2Physician Office Laboratory Markets, 3rd Edition 3Large Volume Wearable Injectors - 2nd Edition 2Large Volume Wearable Injectors - 2nd Edition 3Large Volume Wearable Injectors - 2nd Edition 4Large Volume Wearable Injectors - 2nd Edition 5SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3
... 3 Australian researchers have developed gene expression ... colorectal growths from non-cancerous controls. , , ... conference in Chicago, the preliminary findings are the ... Flinders University and Australian healthcare company, Clinical Genomics ...
... Day 3 And All Subsequent Study Visits - , ... Pharma Co., Ltd., (DSP) announced today that positive results from ... of patients with schizophrenia have been published in The ... placebo-controlled trial, involving 180 patients with acute schizophrenia, evaluated a ...
Cached Medicine Technology:Advance in Bowel Cancer Test Research 2Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry 2Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry 3Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry 4
(Date:9/23/2014)... Dr. Connie Casad has announced that she will be relocating ... 12200 Park Central Drive, Suite 200, Dallas, Texas 75251 on ... Aesthetics, Optimal Health and Wellness, her gynecology practice and concierge ... said, “The patients’ comfort and satisfaction are our primary goal. ... always feel like their needs are valued and recognized by ...
(Date:9/23/2014)... rapidly developing, bringing with its advances promises of ... and treatment interventions. Genetic tests are already ... and hepatitis c virus (HPC), and emerging research ... screen for an individual,s susceptibility to addiction to ... , While there appear to be many benefits ...
(Date:9/23/2014)... News) -- Few children who take medication for ... the rates vary six-fold across counties in the ... alone can manage symptoms for many children with ... receive behavioral therapy (psychotherapy), the Rand Corp. researchers ... than 1,500 counties across the United States that ...
(Date:9/23/2014)... Both patients and healthcare professionals believe diagnosis of ... greatly outweighs the potential disadvantages of subsequent radiologic ... according to a new study published in the ... , Diagnostic tests used for cancer screening programs ... for colorectal cancer with CT colonography, abdominal and ...
(Date:9/23/2014)... Boston, MA (PRWEB) September 23, 2014 ... announced that $50,000 investments each were made to ... the top two health ventures with business solutions to ... , SOURCE is a first-of-its-kind collaboration between The ... Investors' Circle that connects entrepreneurs with the investment ...
Breaking Medicine News(10 mins):Health News:Dr. Connie Casad Moving to New Office Location 2Health News:NYU-Mount Sinai Beth Israel study explores drug users' opinions on genetic testing 2Health News:Kids Taking ADHD Drugs Get Little Psychotherapy: Study 2Health News:Patients accept false-positives to achieve diagnostic sensitivity 2Health News:Patients accept false-positives to achieve diagnostic sensitivity 3Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 2Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 3Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 4Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 5
... talked about by only 20% of patients , , MONDAY, ... rheumatoid arthritis (RA) may be at increased risk for ... says a U.S. study that included 200 RA patients ... Betsy Sleath, of the University of North Carolina at ...
... Feb. 11 CAQH announced today,that the eligibility ... for Information Exchange (CORE) Phase I rules is ... Panel,s (HITSP) first set,of interoperability standards. These standards ... Mike Leavitt late last month., This recognition ...
... Feb. 11 The Employer Support of the ... Alliance to,its list of companies that provide extra-ordinary ... Reserves., National ESGR Executive Director Dr. Gordon ... gathering of the company,s leadership Sunday,in Westlake Village. ...
... Chesapeake Corporation,(NYSE: CSK ), a leading international ... supplier of printed pharmaceutical,leaflets in North America, today ... on Long Island, N.Y., and relocating,from its current ... "Our business has grown substantially since we moved ...
... at Childrens Hospital of Pittsburgh of UPMC have identified a ... the development of a vaccine to prevent and new therapies ... Research led by Jay K. Kolls, MD, chief of the ... identified for the first time the importance of a protein ...
... MINNEAPOLIS, Feb. 11 Uroplasty, Inc. (Amex:,UPI), ... and markets,innovative proprietary products for the treatment ... PC Neuromodulation System, its,proprietary, minimally invasive nerve ... bladder (OAB) symptoms, will be,featured in three ...
Cached Medicine News:Health News:Depression Rarely Discussed With RA Patients 2Health News:CAQH Core Rules Final Component of HITSP Interoperability Standards Formally Recognized By HHS Sec. Leavitt 2Health News:CAQH Core Rules Final Component of HITSP Interoperability Standards Formally Recognized By HHS Sec. Leavitt 3Health News:TriWest Named 'Top-Level' Employer of Guard, Reserve Troops 2Health News:Chesapeake to Expand and Relocate North American Pharmaceutical Packaging Operation 2Health News:Children's Hospital scientists identify possible target for prevention and treatment of pneumonia 2Health News:Studies on Urgent(R) PC to be Presented at the 2008 Society of Urologic Nurses and Associates Annual Symposium 2
... nebulizers offer a spill-proof design and effective ... 45° angle. All medical nebulizers are free-standing ... of configurations are available., ,All Portex® ... ,Portex® medication nebulizers feature consistently fine misting ...
... nebulizers offer a spill-proof design and effective ... 45° angle. All medical nebulizers are free-standing ... of configurations are available., ,All Portex® ... ,Portex® medication nebulizers feature consistently fine misting ...
... This convenient, procedural kit contains everything ... the methacholine challenge test quickly and efficiently: ... gas supply tubing, syringe and needle., ... available in the European Community., ,Intended ...
... Hand Held Nebulizer can be held at angles ... has a built in spill column, finger grooves ... medication setups and 7 feet of regular oxygen ... maintain small particle size and sustain optimum mist ...
Medicine Products: